David Cruikshank

Part of Flynn Management LLC, Deerfield Management LP is a company that provides investment advice. The company is based in New York, NY. Michael A. Foley has been the CEO of the company since 2018.

The Bill & Melinda Gates Foundation was formed in 1997 as the William H. Gates Foundation. In 1999, the foundation was renamed the Bill & Melinda Gates Foundation. The Bill & Melinda Gates Foundation Trust was created in January 2000 through the merger of the Gates Learning Foundation, which worked to expand access to technology through public libraries and the William H. Gates Foundation, which focused on improving global health. The foundation participates in preventive approaches and collaborative endeavors with government, philanthropic and not-for-profit partners. Priority is given to grants that leverage additional support and serve as a catalyst for long-term, systemic change. The foundation also provides funds to promote greater equity in global health, education and public libraries. Through their partnerships in communities across the US, the Bill & Melinda Gates Foundation is committed to raising the high school graduation rate and helping all students, regardless of race or family income. The foundation is headquartered in Seattle, Washington.

ARCH Venture Partners LLC is a Venture Capital firm founded in 1986. The firm is headquartered in Chicago with additional office in Dublin.

Nanosys, Inc. develops and manufactures inorganic nanostructures and other related products. It offers Ultra HD television. The company was founded by Paul A. Alivisatos, Stephen Empedocles, Peidong Yang, Robert M. Metcalfe, Jim Heath, Paul McEuen, Christoph H. Westphal, Moungi Bawendi, Lawrence A. Bock, Calvin Y. H. Chow, Chunming Niu, Karen Vergura, Hongkun Park, George Pontis and Charles M. Lieber in 2001 and is headquartered in Milpitas, CA.

Element Science, Inc. operates as a medical device and digital health company. It develops a wearable platform solution with proprietary technology in wearable patches, electrical design, machine learning algorithms and digital solutions. The company was founded by Uday N. Kumar in 2011 and is headquartered in San Francisco, CA.

Farapulse, Inc. engages in the development of medical devices. Its products are: Endo Farawave, a percutaneous catheter designed to create transmural and contiguous lesions on the endocardium of the left atrium to isolate the pulmonary veins and EPI Faraone, s designed to create a box lesion around all pulmonary veins from an epicardial placement of the catheter for the treatment of atrial fibrillation. The company was founded by Steven Mickelsen in 2014 and is headquartered in Iowa City, IA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Sanford C. Bernstein & Co. LLC is a registered broker-dealer headquartered in New York City. The firm was founded in 1967 and is a subsidiary of Alliance Capital Management LLC, ultimately held by Equitable Holdings, Inc. (NYSE: EQH). Sanford C. Bernstein & Co. provides trading and executions services to their clients.

Healthcare Royalty Management LLC (Healthcare Royalty) is a private equity subsidiary of Cowen, Inc. founded in 2007 by Gregory Brown. The firm is headquartered in Stamford, Connecticut.

InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA.

Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA.

Epic Sciences, Inc. develops novel diagnostics to the treatment and management of cancer. It develops sensitive diagnostic tests to molecularly characterize circulating tumor cells in the blood. The firm also offers fluid-phase biopsy that identifies rare cell of interest in the blood; and provides cancer management through earlier diagnosis, staging and therapeutic selections. The company was founded by David M. Nelson in 2008 and is headquartered in San Diego, CA.

V-Wave Ltd. engages in the development of implantable medical device for treating chronic heart failure. It offers V-Wave Shunt, which is a biocompatible inter-atrial unidirectional implant. The company was founded by Gad Keren and Yaacov Nitzan in 2009 and is headquartered in Caesarea, Israel.

BlueTalon, Inc. provides unmatched data entitlement solutions. It offers single-click data collaboration and data unification technology. The company was founded by Pratik Verma in 2013 and is headquartered in Sunnyvale, CA.

Verana Health, Inc. engages in the development of software solutions for remote patient monitoring and data analytics. It focuses on bridging the gap between healthcare providers and patients with mobile tests. The company was founded by Mark S. Blumenkranz and Daniel V. Palanker in 2008 and is headquartered in San Francisco, CA.

Axon Therapies, Inc. develops treatment for heart failure. The company is headquartered in New York, NY.

Deerfield Management Co. LP (Private Equity) (Deerfield) is a private equity subsidiary of Deerfield Management Co. LP founded in 1994. The firm is headquartered in the New York.

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.

Biomatics Capital Management Co LLC (Biomatics Capital) is a venture capital firm founded in 2016 by Boris Nikolic and Julie Sunderland. The firm is headquartered in Seattle, Washington.

CathWorks Ltd. develops medical devices for the interventional cardiology market. Its technology is based on processing visual information and automatic multi-layered algorithms. The company was founded by Guy Lavi and Ifat Lavi in 2013 and is headquartered in Raanana, Israel.

MTrap, Inc. engages in the development of novel therapeutic devices that interfere with the intense dialogue and crosstalk between the primary tumor and the microenvironment and represent a new disruptive approach to cancer treatment. The company was founded by Maybelle L. Jordan and is headquartered in Huntington, NY.

eGenesis, Inc. operates research platform to deliver human transplantable cells, tissues, and organs grown in pigs. It uses gene editing technology such as CRISPR to directly address the key virology and immunology hurdles that have impeded xenotransplantation. The company was founded by George M. Church, Yang Luhan, Prashant Mali, Geoff Mackay and Guell Marc in 2015 and is headquartered in Cambridge, MA.

Medical Microinstruments SpA develops and manufactures surgical micro-instruments. The firm focuses on clinical outcomes for patients undergoing microsurgery, and offers advanced microsurgical procedures, while reducing costs for patients, hospitals and for society at large. The company was founded by Giuseppe Prisco, Hannah Teichmann and Massimiliano Simi in 2015 and is headquartered in Calci, Italy.

Mount Sinai Genomics, Inc. operates online predictive health analysis platform for diagnosis, treatment and prevention of diseases. It offers Centrellis which analyzes and interprets extensive information about known inherited diseases, including related mutations, frequency across populations, and the penetrance and expressivity of genetic changes. The company was founded by Eric Schadt and is headquartered in Stamford, CT.

Elpiscience Biopharma Ltd. engages in the development of cutting-edge immunotherapies to fight cancer. Its business scope includes technology research and development, transfer of own technology achievements and provision of related technical advice and technical services of biomedicine and biotechnology; import and export, and wholesale of mechanical equipment, electronic products, instrumentation, and plastic products. The company was founded on September 30, 2017 and is headquartered in Shanghai, China.

Reprieve Cardiovascular, Inc. engages in the manufacturing of medical devices. The firm develops device to treat patients suffering from acute decompensated heart failure (ADHF). The company is headquartered in Milford, MA.

Geneception, Inc. provides healthcare services. The company is headquartered in Cambridge, MA.

Endogena Therapeutics, Inc. develops endogenous regenerative medicines. The company was founded by Matthias Steger and Gisbert Schneideri and is headquartered in San Francisco, CA.

Coagulo Medical Technologies, Inc. engages in the provision of precision-medicine platform for coagulation management. The company was founded by Galit Frydman and is headquartered in Auburndale, MA.

Eluminex Biosciences (Suzhou) Ltd. is a privately held biotechnology company located in Suzhou, China. Eluminex Biosciences is committed to developing innovative pharmaceuticals, drug delivery systems, and regenerative tissue for significant unmet vision-threatening or lifestyle limiting ophthalmic diseases in various markets. The Chinese company focuses on ophthalmology and recombinant human collagen technology, with a goal to become a leading healthcare company in developing irreversible loss of optical quality of the cornea due to disease or damage, diabetic macular edema, and wet age-related macular degeneration. The company was founded in 2020 by Jin Zhong Zhang, who has been the CEO since then.

Adela, Inc. is a company that is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). The company is based in Branford, CT. The company's genome-wide methylome enrichment platform captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. Adela's approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample. The CEO of the company is Scott Bratman.

Pleno, Inc. is a company that specializes in multi-omic instrument platform technology for clinical testing and biomedical research. The company is based in San Diego, CA and was founded by Pieter van Rooyen, who has been the CEO since incorporation. The company's proprietary hypercoding™ technology uses signal processing techniques to provide targeted biological information with exceptional scale, precision, and performance.

Scale Biosciences, Inc. is an American single-cell sequencing solutions company that aims to unlock the potential of single-cell analysis at scale by eliminating barriers to discovery. The private company has R & D facilities in Menlo Park, CA and another location that is not specified. The company is located in the US. Scalebio is financed by leading life sciences tools investors Arch Venture Partners, BNG, and Tao Capital. The company's multidisciplinary team of scientists and technologists has combined expertise in next-generation sequencing, genomics, proteomics, and bioinformatics. Discover how their single-cell sequencing technology enables scalable sample indexing, cell throughput, and multi-omics analysis.

Aurion Biotech, Inc. is a clinical-stage biotech company with offices in multiple locations. Aurion Biotech has initiated clinical trials in the US in 2023. The company is based in Seattle, WA. The company's mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech has received the prestigious Prix Galien award for best start-up in biotech. The company's first candidate is an off-the-shelf, clinically validated cell therapy for corneal care, which has received regulatory approval. The company is privately held and backed by leading investors, including Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures. Greg Kunst has been the CEO of the company since 2021.